Metabolic Syndrome & Insulin Resistance

Metabolic syndrome, insulin resistance, prediabetes physiology, and cardiometabolic risk.

RCT Diabetes Prevention

DREAM: Rosiglitazone Reduces Diabetes Incidence by 60% in Pre-Diabetes — A Landmark Trial Overtaken by Safety

The DREAM trial demonstrated that rosiglitazone reduces incident diabetes or death by 60% and achieves normoglycaemia in 50% of high-risk adults with impaired glucose tolerance, the largest pharmacological diabetes prevention effect documented in a large RCT, but the drug's subsequent cardiovascular safety concerns and market withdrawal have prevented translation of these findings into clinical practice.

Subscribe now

Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.

© 2024-2026 Hormone Insight. All rights reserved.